PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today ...

Singapore-based biotechnology company CytoMed Therapeutics has signed a five-year business and research collaboration ...

SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a ...

CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable immunotherapy solutions.

TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, ...

Additionally, IN8bio management will be in San Francisco from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.

TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, ...

About the Phase 1 First-in-human Study of LAVA-1266 (ACTRN12624001214527) ...